Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES ALLRED

Allopathic & Osteopathic Physicians Dermatology

NPI
1780946160
CMS profile
262344
Location
FRANKLIN, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$228,010.16

239 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES ALLRED

NPI 1780946160 · CMS profile ID 262344

Allopathic & Osteopathic Physicians / Dermatology

FRANKLIN, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780946160?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES ALLRED, NPI 1780946160, CMS profile ID 262344. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780946160?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMES ALLRED, NPI 1780946160, CMS profile ID 262344. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780946160?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMES ALLRED, NPI 1780946160, CMS profile ID 262344, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780946160?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

239 matching records · $228,010.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 239 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 239.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $17.5406/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201401084 CMS
Janssen Biotech, Inc. $33.3106/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174496810 CMS
Janssen Biotech, Inc. $59.9906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174497043 CMS
Janssen Biotech, Inc. $40.0006/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174497065 CMS
ABBVIE INC. $27.0106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201401082 CMS
Janssen Biotech, Inc. $3.3006/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174496780 CMS
Janssen Biotech, Inc. $714.9706/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174496922 CMS
Janssen Biotech, Inc. $182.9006/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174496942 CMS
Janssen Biotech, Inc. $347.9406/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174497083 CMS
Galderma Laboratories, L.P. $1,680.0006/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234613365 CMS
UCB, Inc. $21.4906/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653294 CMS
UCB, Inc. $6.2406/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653289 CMS
UCB, Inc. $39.1006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653286 CMS
Incyte Corporation $28.9706/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225994110 CMS
Regeneron Healthcare Solutions, Inc. $21.0006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212860854 CMS
ABBVIE INC. $3.7906/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201401080 CMS
UCB, Inc. $22.4106/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653283 CMS
Janssen Biotech, Inc. $6.2305/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174497021 CMS
Novartis Pharmaceuticals Corporation $13.9305/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200152008 CMS
Amgen Inc. $20.7305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228450570 CMS
Organon LLC $5,400.0005/15/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1237774492 CMS
UCB, Inc. $5,000.0005/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224653279 CMS
Galderma Laboratories, L.P. $14.9705/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234613363 CMS
Arcutis Biotherapeutics, Inc. $16.0005/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252346137 CMS
UCB, Inc. $15.0005/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224653275 CMS
Organon LLC $123.2305/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237774462 CMS
Organon LLC $1,500.3605/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237774482 CMS
Novartis Pharmaceuticals Corporation $26.6505/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200152010 CMS
Amgen Inc. $3,750.0005/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226884285 CMS
UCB, Inc. $5.1104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653271 CMS
Amgen Inc. $18.8404/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228450574 CMS
Amgen Inc. $1,562.5004/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226883978 CMS
Krystal Biotech Inc $24.4804/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199995390 CMS
UCB, Inc. $118.5304/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653266 CMS
ABBVIE INC. $22.0004/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201401078 CMS
UCB, Inc. $22.8204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224653263 CMS
Galderma Laboratories, L.P. $8,100.0004/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234613359 CMS
Galderma Laboratories, L.P. $2,250.0004/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234613361 CMS
UCB, Inc. $1,725.0004/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224653254 CMS
UCB, Inc. $5,000.0004/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224653259 CMS
Galderma Laboratories, L.P. $5,400.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234613357 CMS
Organon LLC $2,400.0004/16/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1237774484 CMS
Organon LLC $5,400.0004/16/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1237774490 CMS
Galderma Laboratories, L.P. $1,237.2804/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234613355 CMS
Galderma Laboratories, L.P. $94.8804/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234613351 CMS
Galderma Laboratories, L.P. $30.0004/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234613353 CMS
Galderma Laboratories, L.P. $2,250.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234613349 CMS
Galderma Laboratories, L.P. $50.3504/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234613347 CMS
Galderma Laboratories, L.P. $11.7804/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234613345 CMS
UCB, Inc. $5,000.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224653250 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,375.94 65
PY2020 $2,244.38 53
PY2021 $5,910.51 34
PY2022 $2,361.25 50
PY2023 $1,354.97 76
PY2024 $51,309.83 130
PY2025 $228,010.16 239

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,496.52 10
PY2025 Principal investigator $2,194,958.43 413
PY2024 Recipient $19,142.54 2
PY2024 Principal investigator $165,149.18 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

423 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,500.00 12/31/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202535277
Principal investigator 1 ABBVIE INC. $783.00 12/30/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202532204
Principal investigator 1 Janssen Research & Development, LLC $9,130.00 12/29/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220843
Principal investigator 1 Janssen Research & Development, LLC $55.00 12/29/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220892
Principal investigator 1 Janssen Research & Development, LLC $10,832.00 12/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220901
Principal investigator 1 ABBVIE INC. $1,170.00 12/24/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202532046
Principal investigator 1 Janssen Research & Development, LLC $375.00 12/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220835
Principal investigator 1 Janssen Research & Development, LLC $55.00 12/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220864
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156684
Principal investigator 1 SANOFI US SERVICES INC. $720.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156701
Principal investigator 1 SANOFI US SERVICES INC. $13,366.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156726
Principal investigator 1 Incyte Corporation $1,300.00 12/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533521
Principal investigator 1 Incyte Corporation $1,300.00 12/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533525
Principal investigator 1 Incyte Corporation $1,800.00 12/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533539
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,339.95 12/18/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431883
Principal investigator 1 Incyte Corporation $1,671.00 12/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533510
Principal investigator 1 Janssen Research & Development, LLC $166.00 12/15/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220850
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 12/15/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220872
Principal investigator 1 SANOFI US SERVICES INC. $3,025.00 12/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156691
Principal investigator 1 SANOFI US SERVICES INC. $7,210.00 12/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156705
Principal investigator 1 Incyte Corporation $3,375.00 12/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533676
Principal investigator 1 Incyte Corporation $1,300.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532975
Principal investigator 1 Incyte Corporation $1,300.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532979
Principal investigator 1 Incyte Corporation $1,000.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533022
Principal investigator 1 ABBVIE INC. $6,000.00 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529866
Principal investigator 1 ABBVIE INC. $2,250.00 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529870
Principal investigator 1 Incyte Corporation $943.96 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533462
Principal investigator 1 Incyte Corporation $1,742.00 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533559
Principal investigator 1 Incyte Corporation $12.47 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533614
Principal investigator 1 Incyte Corporation $56.00 12/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533644
Principal investigator 1 SANOFI US SERVICES INC. $700.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156650
Principal investigator 1 SANOFI US SERVICES INC. $16,200.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156656
Principal investigator 1 SANOFI US SERVICES INC. $3,250.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156659
Principal investigator 1 SANOFI US SERVICES INC. $10,932.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226156673
Principal investigator 1 Incyte Corporation $1,500.00 12/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533467
Principal investigator 1 Incyte Corporation $6,356.10 12/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533505
Principal investigator 1 Incyte Corporation $2,577.00 12/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533665
Principal investigator 1 Incyte Corporation $15,000.00 12/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533680
Principal investigator 1 ABBVIE INC. $1,578.54 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528078
Principal investigator 1 ABBVIE INC. $750.00 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202528080
Principal investigator 1 ABBVIE INC. $12,151.05 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202528110
Principal investigator 1 ABBVIE INC. $8,526.92 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528112
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532988
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532992
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533001
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533006
Principal investigator 1 Incyte Corporation $202.50 11/25/2025 Non-covered Recipient Entity
WELLSKIN DERMATOLOGY & AESTHETICS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240618425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,576.00 11/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 11/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 11/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.00 11/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264531
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,200.00 11/20/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431873
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10.71 11/20/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431880
Principal investigator 1 Incyte Corporation $2,504.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533444
Principal investigator 1 Incyte Corporation $1,689.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533529
Principal investigator 1 Incyte Corporation $1,689.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533534
Principal investigator 1 Incyte Corporation $119.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533600
Principal investigator 1 Incyte Corporation $10,000.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533609
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533617
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533621
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533625
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533628
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533632
Principal investigator 1 Incyte Corporation $49.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533636
Principal investigator 1 Incyte Corporation $530.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533640
Principal investigator 1 Incyte Corporation $355.70 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533648
Principal investigator 1 Incyte Corporation $1,642.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533652
Principal investigator 1 Incyte Corporation $1,642.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533656
Principal investigator 1 Incyte Corporation $1,642.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533661
Principal investigator 1 Incyte Corporation $371.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533668
Principal investigator 1 Incyte Corporation $1,000.00 11/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533732
Principal investigator 1 SANOFI US SERVICES INC. $37,934.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156576
Principal investigator 1 SANOFI US SERVICES INC. $800.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156594
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156598
Principal investigator 1 SANOFI US SERVICES INC. $16,730.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156601
Principal investigator 1 SANOFI US SERVICES INC. $9,438.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156612
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156624
Principal investigator 1 SANOFI US SERVICES INC. $4,250.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157128
Principal investigator 1 ABBVIE INC. $911.25 11/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524301
Principal investigator 1 ABBVIE INC. $2,000.00 11/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524303
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,979.20 11/13/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431865
Principal investigator 1 Incyte Corporation $2,419.00 11/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533736
Principal investigator 1 Incyte Corporation $2,419.00 11/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533740
Principal investigator 1 SANOFI US SERVICES INC. $7,840.00 11/10/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157111
Principal investigator 1 ABBVIE INC. $2,300.00 11/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523195
Principal investigator 1 ABBVIE INC. $2,300.00 11/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523557
Principal investigator 1 ABBVIE INC. $26,019.35 11/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521419
Principal investigator 1 ABBVIE INC. $42,917.11 11/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202521421
Principal investigator 1 ABBVIE INC. $20,236.38 11/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523115
Principal investigator 1 SANOFI US SERVICES INC. $18,500.00 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226157106
Principal investigator 1 SANOFI US SERVICES INC. $1,258.30 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157115
Principal investigator 1 SANOFI US SERVICES INC. $17,290.00 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157124
Principal investigator 1 ABBVIE INC. $10,935.00 10/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202518673
Principal investigator 1 ABBVIE INC. $600.00 10/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202518675
Principal investigator 1 ABBVIE INC. $5,791.50 10/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202518677
Principal investigator 1 ABBVIE INC. $67.50 10/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202518679
Principal investigator 1 ABBVIE INC. $4,677.75 10/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202518681
Principal investigator 1 Janssen Research & Development, LLC $2,252.00 10/24/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220818
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,095.65 10/23/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431856
Principal investigator 1 ABBVIE INC. $1,980.00 10/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517637
Principal investigator 1 ABBVIE INC. $6,000.00 10/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517639
Principal investigator 1 ABBVIE INC. $1,980.00 10/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517641
Principal investigator 1 ABBVIE INC. $4,500.00 10/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517651
Principal investigator 1 ABBVIE INC. $4,500.00 10/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202517653
Principal investigator 1 SANOFI US SERVICES INC. $12,420.80 10/20/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157085
Principal investigator 1 SANOFI US SERVICES INC. $14,865.00 10/20/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157097
Principal investigator 1 ABBVIE INC. $3,240.00 10/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517359
Principal investigator 1 ABBVIE INC. $742.50 10/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517361
Principal investigator 1 ABBVIE INC. $1,500.00 10/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517363
Principal investigator 1 ABBVIE INC. $1,633.50 10/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517365
Principal investigator 1 ABBVIE INC. $3,719.25 10/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517367
Principal investigator 1 SANOFI US SERVICES INC. $16,100.00 10/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157066
Principal investigator 1 Incyte Corporation $62.97 10/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533027
Principal investigator 1 Incyte Corporation $10,000.00 10/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533042
Principal investigator 1 Incyte Corporation $912.00 10/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533070
Principal investigator 1 Incyte Corporation $912.00 10/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533074
Principal investigator 1 ABBVIE INC. $4,050.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515877
Principal investigator 1 ABBVIE INC. $1,474.20 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202515919
Principal investigator 1 ABBVIE INC. $37,639.13 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516435
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533441
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533448
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533451
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533454
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533458
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533464
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533471
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533473
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533478
Principal investigator 1 Incyte Corporation $1,689.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533481
Principal investigator 1 Incyte Corporation $1,689.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533486
Principal investigator 1 Incyte Corporation $1,689.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533489
Principal investigator 1 Incyte Corporation $1,689.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533494
Principal investigator 1 Incyte Corporation $49.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533498
Principal investigator 1 Incyte Corporation $1,779.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533513
Principal investigator 1 Incyte Corporation $1,779.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533517
Principal investigator 1 Incyte Corporation $1,779.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533543
Principal investigator 1 Incyte Corporation $1,779.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533547
Principal investigator 1 Incyte Corporation $1,779.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533551
Principal investigator 1 Incyte Corporation $1,717.20 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533555
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533565
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533568
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533572
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533576
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533580
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533584
Principal investigator 1 Incyte Corporation $2,504.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533588
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533685
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533690
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533694
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533698
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533702
Principal investigator 1 Incyte Corporation $119.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533705
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533710
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533714
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533718
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533720
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533725
Principal investigator 1 Incyte Corporation $1,588.00 10/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533728
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,300.40 10/09/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431847
Principal investigator 1 ABBVIE INC. $5,954.57 10/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513567
Principal investigator 1 Incyte Corporation $1,715.00 10/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533592
Principal investigator 1 Incyte Corporation $1,715.00 10/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533596
Principal investigator 1 Novartis Pharmaceuticals Corporation $117,464.04 10/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190313041
Principal investigator 1 SANOFI US SERVICES INC. $4,900.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157041
Principal investigator 1 SANOFI US SERVICES INC. $3,700.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157050
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157054
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157057
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157062
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533501
Principal investigator 1 Incyte Corporation $2,600.00 10/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533605
Principal investigator 1 Incyte Corporation $15,000.00 10/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240533672
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532953
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532958
Principal investigator 1 Incyte Corporation $54.76 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532961
Principal investigator 1 Incyte Corporation $54.76 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532964
Principal investigator 1 Incyte Corporation $57.25 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532967
Principal investigator 1 Incyte Corporation $12.72 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532972
Principal investigator 1 Incyte Corporation $64.72 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532984
Principal investigator 1 Incyte Corporation $22.90 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532997
Principal investigator 1 Incyte Corporation $48.54 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533011
Principal investigator 1 Incyte Corporation $59.13 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533015
Principal investigator 1 Incyte Corporation $59.13 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533019
Principal investigator 1 Incyte Corporation $9.72 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533031
Principal investigator 1 Incyte Corporation $32.36 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533033
Principal investigator 1 Incyte Corporation $68.70 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533038
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533046
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533050
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533055
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533058
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533062
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533065
Principal investigator 1 Incyte Corporation $14.84 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533078
Principal investigator 1 Incyte Corporation $62.27 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533081
Principal investigator 1 Incyte Corporation $62.27 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533085
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533089
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533093
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533097
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240533100
Principal investigator 1 SANOFI US SERVICES INC. $18,570.00 09/29/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157037
Principal investigator 1 Amgen Inc. $8,000.00 09/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246641273
Principal investigator 1 Incyte Corporation $2,577.00 09/23/2025 Non-covered Recipient Entity
WELLSKIN DERMATOLOGY & AESTHETICS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240618409
Principal investigator 1 Incyte Corporation $15,000.00 09/23/2025 Non-covered Recipient Entity
WELLSKIN DERMATOLOGY & AESTHETICS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240618417
Principal investigator 1 Incyte Corporation $1,500.00 09/23/2025 Non-covered Recipient Entity
WELLSKIN DERMATOLOGY & AESTHETICS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240618421
Principal investigator 1 SANOFI US SERVICES INC. $26,697.00 09/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157031
Principal investigator 1 Incyte Corporation $4,375.00 09/18/2025 Non-covered Recipient Entity
WELLSKIN DERMATOLOGY & AESTHETICS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240618413
Principal investigator 1 ABBVIE INC. $6,000.00 09/16/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511012
Principal investigator 1 Eli Lilly and Company $11,691.00 09/15/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880919
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,000.00 09/11/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431839
Principal investigator 1 ABBVIE INC. $337.50 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510442
Principal investigator 1 ABBVIE INC. $1,174.50 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510444
Principal investigator 1 ABBVIE INC. $2,430.00 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510448
Principal investigator 1 ABBVIE INC. $1,500.00 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510452
Principal investigator 1 ABBVIE INC. $2,592.00 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510454
Principal investigator 1 ABBVIE INC. $346.50 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510538
Principal investigator 1 ABBVIE INC. $364.50 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510540
Principal investigator 1 ABBVIE INC. $1,004.40 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510542
Principal investigator 1 Incyte Corporation $1,715.00 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532885
Principal investigator 1 Incyte Corporation $1,715.00 09/10/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532930
Principal investigator 1 Eli Lilly and Company $6,075.14 09/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187881740
Principal investigator 1 Eli Lilly and Company $73,263.00 09/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187880241
Principal investigator 1 Janssen Research & Development, LLC $3,514.00 09/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220857
Principal investigator 1 Lilly USA, LLC $107,623.00 09/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
Not supplied No dispute reported 06/30/2026 1187880243
Principal investigator 1 Incyte Corporation $2,934.00 09/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532833
Principal investigator 1 Incyte Corporation $125.00 09/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532837
Principal investigator 1 Incyte Corporation $221.00 09/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532862
Principal investigator 1 Incyte Corporation $2,616.00 09/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532934
Principal investigator 1 SANOFI US SERVICES INC. $25,883.10 09/03/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157022
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/25/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157006
Principal investigator 1 SANOFI US SERVICES INC. $10,548.00 08/25/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157009
Principal investigator 1 ABBVIE INC. $5,000.00 08/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505361
Principal investigator 1 ABBVIE INC. $5,000.00 08/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505363
Principal investigator 1 ABBVIE INC. $5,000.00 08/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505375
Principal investigator 1 SANOFI US SERVICES INC. $27,590.21 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156987
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $39,036.66 08/06/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431828
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,858.05 08/06/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431835
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532902
Principal investigator 1 Incyte Corporation $45.80 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532911
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532917
Principal investigator 1 Incyte Corporation $4.86 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532922
Principal investigator 1 Incyte Corporation $0.62 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532938
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532941
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532945
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532950
Principal investigator 1 Incyte Corporation $2,422.00 08/01/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532866
Principal investigator 1 Janssen Research & Development, LLC $9,269.00 07/31/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220826
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 07/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156943
Principal investigator 1 Incyte Corporation $265.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532829
Principal investigator 1 Incyte Corporation $564.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532850
Principal investigator 1 Incyte Corporation $904.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532855
Principal investigator 1 Incyte Corporation $128.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532859
Principal investigator 1 Incyte Corporation $139.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532870
Principal investigator 1 Incyte Corporation $7,034.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532874
Principal investigator 1 Incyte Corporation $124.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532877
Principal investigator 1 Incyte Corporation $725.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532881
Principal investigator 1 Incyte Corporation $54.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532889
Principal investigator 1 Incyte Corporation $135.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532892
Principal investigator 1 Incyte Corporation $89.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532898
Principal investigator 1 Incyte Corporation $290.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532926
Recipient Eli Lilly and Company $901.63 07/17/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187873457
Principal investigator 1 SANOFI US SERVICES INC. $4,701.00 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156825
Principal investigator 1 SANOFI US SERVICES INC. $3,896.11 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156829
Principal investigator 1 SANOFI US SERVICES INC. $5,118.10 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156897
Principal investigator 1 SANOFI US SERVICES INC. $15,295.00 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156908
Principal investigator 1 Incyte Corporation $1,715.00 07/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532895
Principal investigator 1 Incyte Corporation $1,715.00 07/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532907
Principal investigator 1 Incyte Corporation $1,114.00 07/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532841
Principal investigator 1 Incyte Corporation $2,118.00 07/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532846
Principal investigator 1 ABBVIE INC. $15,427.20 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495273
Principal investigator 1 ABBVIE INC. $24,018.90 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202495275
Principal investigator 1 ABBVIE INC. $20,632.57 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495277
Principal investigator 1 SANOFI US SERVICES INC. $102,501.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156833
Principal investigator 1 SANOFI US SERVICES INC. $24,061.40 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156922
Principal investigator 1 Janssen Research & Development, LLC $19,725.00 06/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220885
Principal investigator 1 SANOFI US SERVICES INC. $16,900.00 06/23/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156850
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115029
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115031
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115033
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115035
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115037
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115039
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115041
Principal investigator 1 Incyte Corporation $1,715.00 06/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532682
Principal investigator 1 Incyte Corporation $1,715.00 06/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532815
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $12,500.00 06/05/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431818
Principal investigator 1 Incyte Corporation $1,289.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532613
Principal investigator 1 Incyte Corporation $3,006.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532628
Principal investigator 1 Incyte Corporation $1,875.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532647
Principal investigator 1 Incyte Corporation $2,824.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532652
Principal investigator 1 Incyte Corporation $2,894.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532663
Principal investigator 1 Incyte Corporation $440.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532685
Principal investigator 1 Incyte Corporation $3,006.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532766
Principal investigator 1 Incyte Corporation $1,289.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532776
Principal investigator 1 ABBVIE INC. $5,795.10 06/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202489051
Principal investigator 1 ABBVIE INC. $8,032.60 06/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489053
Recipient Regeneron Pharmaceuticals, Inc. $486.05 05/28/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115027
Principal investigator 1 Janssen Research & Development, LLC $7,304.00 05/26/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175220880
Principal investigator 1 ABBVIE INC. $25,760.15 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482601
Principal investigator 1 ABBVIE INC. $19,875.00 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482603
Principal investigator 1 ABBVIE INC. $4,568.55 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202482605
Principal investigator 1 Incyte Corporation $1,883.00 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532672
Principal investigator 1 Incyte Corporation $1,742.00 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532677
Principal investigator 1 Incyte Corporation $2.75 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532606
Principal investigator 1 Incyte Corporation $73.80 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532609
Principal investigator 1 Incyte Corporation $2,874.00 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532617
Principal investigator 1 Incyte Corporation $84.90 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532620
Principal investigator 1 Incyte Corporation $17.20 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532624
Principal investigator 1 Incyte Corporation $119.08 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532701
Principal investigator 1 Incyte Corporation $6.76 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532708
Principal investigator 1 Incyte Corporation $117.56 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532742
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532762
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532819
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532825
Principal investigator 1 SANOFI US SERVICES INC. $24,194.40 04/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156801
Principal investigator 1 Incyte Corporation $2,419.00 04/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532656
Principal investigator 1 Incyte Corporation $1,742.00 04/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532659
Principal investigator 1 Incyte Corporation $1,883.00 04/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532668
Principal investigator 1 ABBVIE INC. $5,281.35 04/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202471680
Principal investigator 1 ABBVIE INC. $8,736.27 04/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202471684
Principal investigator 1 Incyte Corporation $2.94 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532631
Principal investigator 1 Incyte Corporation $48.54 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532634
Principal investigator 1 Incyte Corporation $58.78 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532638
Principal investigator 1 Incyte Corporation $3,006.00 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532642
Principal investigator 1 Incyte Corporation $12.15 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532690
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532694
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532697
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532705
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532712
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532717
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532721
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532726
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532731
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532735
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532739
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532746
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532751
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532758
Principal investigator 1 Incyte Corporation $1.47 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532772
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532780
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532784
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532789
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532793
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532797
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532801
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532806
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532811
Principal investigator 1 SANOFI US SERVICES INC. $22,985.80 03/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156758
Principal investigator 1 Incyte Corporation $1,827.00 03/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532353
Principal investigator 1 Incyte Corporation $2,419.00 03/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532357
Principal investigator 1 Incyte Corporation $1,854.00 03/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532364
Principal investigator 1 Incyte Corporation $1,827.00 03/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532372
Principal investigator 1 ABBVIE INC. $14,322.53 03/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202461337
Principal investigator 1 ABBVIE INC. $19,152.03 03/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202461341
Principal investigator 1 Eli Lilly and Company $2,281.96 03/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880595
Principal investigator 1 SANOFI US SERVICES INC. $16,900.00 03/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156755
Principal investigator 1 Incyte Corporation $7.29 03/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532531
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532535
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532539
Principal investigator 1 SANOFI US SERVICES INC. $10,248.80 02/24/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156743
Principal investigator 1 Incyte Corporation $2,643.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532340
Principal investigator 1 Incyte Corporation $1,715.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532349
Principal investigator 1 Incyte Corporation $2,643.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532582
Principal investigator 1 Incyte Corporation $2,643.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532586
Principal investigator 1 Incyte Corporation $1,742.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532590
Principal investigator 1 Incyte Corporation $1,854.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532593
Principal investigator 1 Incyte Corporation $1,854.00 02/19/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532597
Principal investigator 1 Incyte Corporation $2,577.00 02/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532345
Principal investigator 1 Incyte Corporation $14,618.00 02/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532361
Principal investigator 1 Incyte Corporation $1,500.00 02/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532368
Principal investigator 1 ABBVIE INC. $4,602.90 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202449216
Principal investigator 1 ABBVIE INC. $17,811.59 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449221
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532391
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532395
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532399
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532404
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532413
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532416
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532424
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532429
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532433
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532441
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532445
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532449
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532453
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532458
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532462
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532466
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532470
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532474
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532479
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532483
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532488
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532492
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532495
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532500
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532504
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532509
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532513
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532517
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532522
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532526
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532543
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532547
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532551
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532555
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532559
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532575
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240532601
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533437
Recipient Eli Lilly and Company $3,900.62 01/27/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187872421
Principal investigator 1 Eli Lilly and Company $169,960.00 01/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880297
Principal investigator 1 Incyte Corporation $1,715.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532375
Principal investigator 1 Incyte Corporation $2,643.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532379
Principal investigator 1 Incyte Corporation $1,827.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532383
Principal investigator 1 Incyte Corporation $1,827.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532387
Principal investigator 1 Incyte Corporation $1,715.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532564
Principal investigator 1 Incyte Corporation $1,715.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532568
Principal investigator 1 Incyte Corporation $1,715.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532571
Principal investigator 1 Incyte Corporation $2,643.00 01/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532577
Principal investigator 1 Eli Lilly and Company $160,032.00 01/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187882918
Principal investigator 1 ABBVIE INC. $4,517.93 01/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202435631
Principal investigator 1 Incyte Corporation $137.40 01/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532407
Principal investigator 1 Incyte Corporation $12.15 01/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532420
Principal investigator 1 Incyte Corporation $812.40 01/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240532437